Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13200MR)

This product GTTS-WQ13200MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hyperlipidemia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13200MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13102MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ13769MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ3724MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ3595MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ13379MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ3138MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ9073MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ2120MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW